Ipamorelin: The Complete 2026 Research Guide to Selective GH Secretagogues

What Is Ipamorelin? Mechanism of Action

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide that functions as a selective agonist of the growth hormone secretagogue receptor 1a (GHSR-1a) — the same receptor activated by the endogenous hormone ghrelin. By binding GHSR-1a on somatotroph cells in the anterior pituitary, ipamorelin stimulates the pulsatile release of growth hormone in a dose-dependent manner.

Unlike endogenous ghrelin, which also influences appetite, gastric motility, and metabolic signaling through peripheral GHSR-1a expression, ipamorelin’s primary characterized effect in research models has been focused on the GH axis. Its structural design — lacking the central Ala-Trp dipeptide of GHRP-1 — was the key innovation that produced its exceptional selectivity profile.

The compound was first described by Raun et al. in 1998, who characterized it as “the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.” That landmark characterization remains the foundation of ipamorelin’s research profile nearly three decades later.^[1]

Why “Selective” Matters in GH Research

The term selective is not marketing language — it has measurable pharmacological meaning. Growth hormone secretagogues as a class stimulate GH release, but most also activate the hypothalamic-pituitary-adrenal (HPA) axis to varying degrees, elevating ACTH and cortisol. In research settings, this creates a confounding variable: observed anabolic or metabolic effects may partially reflect glucocorticoid activity rather than GH signaling alone.

Ipamorelin resolves this problem. In the pivotal Raun et al. swine study, ipamorelin did not raise ACTH or cortisol levels significantly — even at doses more than 200-fold higher than its GH-releasing ED50. FSH, LH, prolactin, and TSH were similarly unaffected. This makes ipamorelin an unusually clean tool for isolating GH-specific effects in preclinical models.

Ipamorelin vs. GHRP-2, GHRP-6, and Hexarelin: Selectivity Profile

Understanding ipamorelin’s position in the GHRP family requires direct comparison. All four compounds bind GHSR-1a, but their off-target hormonal effects differ substantially.

GHRP-2 exhibits the highest GH-releasing potency among this group in swine models (ED50 ~0.6 nmol/kg), but this comes with meaningful ACTH and cortisol elevation. Hexarelin is similarly potent but carries the additional concern of cardiovascular receptor binding. Ipamorelin’s GH potency is comparable to GHRP-6 (ED50 ~2.3 nmol/kg), but without the cortisol, prolactin, or pronounced hunger-stimulating effects — making it the preferred tool in selectivity-focused research.

CJC-1295 + Ipamorelin: Dual-Pathway GH Axis Research

Ipamorelin’s short half-life (~2 hours) means that its GH pulse, while clean, is transient. This biological limitation has driven substantial research interest in combining ipamorelin with CJC-1295, a GHRH analog with a substantially extended half-life due to drug affinity complex (DAC) technology.

The rationale is mechanistic: ipamorelin acts on GHSR-1a (the ghrelin receptor), while CJC-1295 acts on the GHRH receptor (GHRHR). These are distinct receptors activating complementary signaling cascades within pituitary somatotrophs. Concurrent activation of both pathways produces a synergistic GH release — greater in amplitude and duration than either peptide alone.

This dual-pathway approach mirrors the physiological pattern of GH regulation, where natural GH pulses are governed by both GHRH and ghrelin signaling. For researchers investigating GH axis dynamics, the CJC-1295 + Ipamorelin research blend provides a convenient formulation for this combined protocol. For a deeper dive into the CJC-1295 component and its pharmacokinetic profile, see also the related research overview at Ipamorelin: Complete Research Guide.

Half-Life and Research Protocol Considerations

Ipamorelin’s plasma half-life in preclinical models is approximately 2 hours, with peak GH release occurring within 15–30 minutes of administration. The GH pulse typically returns to baseline within 3 hours, making ipamorelin a short-acting but highly predictable secretagogue.

In published preclinical research, ipamorelin has been administered via:

• Subcutaneous (SC) injection — the most common route in rodent and swine models
• Intraperitoneal (IP) injection — used in rodent studies including the Lu et al. 2024 ferret model
• Intravenous (IV) — used in acute dose-response pharmacokinetic studies

Preclinical dose ranges reported in the literature span 1–3 mg/kg for IP and SC administration in small animal models, with conscious swine studies using nmol/kg doses (ED50 ~2.3 nmol/kg SC). Study durations in body composition and metabolic research typically range from 4 to 12 weeks.

It bears repeating that ipamorelin’s selectivity is one of its chief advantages in protocol design: because it does not elevate cortisol or prolactin at research doses, investigators can attribute observed changes in lean mass, fat distribution, IGF-1 levels, and metabolic markers more confidently to GH axis activation rather than glucocorticoid confounding.^[3]

2026 Research Update: GH Secretagogues in Focus

Frequently Asked Questions

What is ipamorelin and how does it work?

Ipamorelin is a synthetic pentapeptide GHSR-1a agonist. It mimics ghrelin to trigger pulsatile GH release from the pituitary without significantly elevating cortisol, prolactin, or ACTH — making it uniquely selective among GHRPs.

How does ipamorelin differ from GHRP-2 and GHRP-6?

While all three activate GHSR-1a, GHRP-2 and GHRP-6 both elevate ACTH and cortisol alongside GH. Ipamorelin does not — even at doses over 200× its GH-releasing ED50. This selectivity is ipamorelin’s defining research advantage.

Why is ipamorelin considered selective?

Selectivity means triggering the target response (GH release) without off-target hormonal activation. Ipamorelin’s GH-only profile — confirmed across FSH, LH, PRL, TSH, ACTH, and cortisol — represents the broadest selectivity demonstrated for any GHRP-receptor agonist.

What is the half-life of ipamorelin?

Approximately 2 hours in preclinical models. GH peaks within 15–30 minutes and returns to baseline by ~3 hours. This is why ipamorelin is often paired with long-acting GHRH analogs like CJC-1295 in research protocols.

Can ipamorelin and CJC-1295 be combined in research?

Yes. CJC-1295 activates the GHRH receptor while ipamorelin activates GHSR-1a — complementary pathways that produce synergistic GH release. The CJC-1295 + Ipamorelin blend is formulated for dual-pathway GH axis research.

What is the research protocol for ipamorelin?

Preclinical studies have used 1–3 mg/kg via SC or IP injection in rodent models, and nmol/kg doses in swine. Study durations typically span 4–12 weeks. Protocols are highly model-dependent and should reference published pharmacokinetic data for each species.

Does ipamorelin affect cortisol levels in research models?

No significant cortisol or ACTH elevation has been observed with ipamorelin in preclinical models, even at supratherapeutic doses. This distinguishes it from GHRP-2 and GHRP-6, both of which raise ACTH and cortisol at standard GH-releasing doses.

References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
2. Lu Z, Ngan MP, Liu JYH, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets. Physiol Behav. 2024;284:114644. PMID: 39043357
3. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID: 32257855